Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy
{{output}}
Background: Tafamidis is a standard of care treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). While evidence was being assessed by regulatory authorities, a new, independent, and inclusive cohort of the ... ...
